Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: MCV4 vaccine - Novartis; MenACWY-CRM; Menveo; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Tianjin CanSino Biotechnology
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 06 Dec 2016 GlaxoSmithKline plans a phase IIIb trial for Meningococcal infections (In adolescents, In adults, Prevention) in USA (IM) (NCT02986854)
  • 01 Oct 2014 Novartis Vaccines completes a phase II trial for Meningococcal group A, C, W-135 infections in infants aged 12-15 months in Italy (NCT01994629)
  • 01 Jun 2014 Phase-III clinical trials in Meningococcal infections (Combination therapy, In infants, Prevention) in Argentina (IM) after June 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top